Employees: 1,800
Size Advanced Medical Solutions (AMS.L) is a United Kingdom Health Care company (Medical Specialties) with a market value of $811M, the 237th largest of 355 United Kingdom companies the cockpit tracks. Shares closed at £283.00 on 18 Nov 2026.
Performance Over six months the shares gained 27.2%, against -15.2% for the median peer and +0.1% for the United Kingdom market (cap-weighted) — 7th highest of 21 in its peer set.
Growth Revenue grew 6.0% over the last twelve months (peer median +7.3%); the operating margin is 12.5% (peer median 9.4%).
Valuation It trades at 20.7× forward earnings against a peer median of 19.9× (5th most expensive of 13).
Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +21%, so the hurdle is -1 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 2.8 points below its cost of capital (9.5% WACC).
Next results Next results expected around 17 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | £234M | £229M | £178M | £126M | £124M |
| Revenue growth | — | +29% | +41% | +2% | — |
| Gross profit | £112M | £109M | £82.8M | £63.7M | £68.6M |
| EBITDA | £51.1M | £48.5M | £37.7M | £30.7M | £34.9M |
| Net income | £3.68M | £9.95M | £7.09M | £15.9M | £20.4M |
| Free cash flow | £7.95M | £21.4M | £12.7M | £10.9M | £23.3M |
| Capital expenditure | £18.0M | £12.6M | £8.74M | £9.85M | £9.96M |
| Total debt | n/a | £81.5M | £86.6M | £9.14M | £9.75M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AMS.L | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +0.3% | -5.1% | 7th highest of 21 |
| 6-month return | +27.2% | -15.2% | 7th highest of 21 |
| Distance from 52-week high | -0.5% | -39.8% | highest of 21 |
| Revenue growth (TTM) | +6.0% | +7.3% | 10th lowest of 21 |
| Operating margin | 12.5% | 9.4% | 8th highest of 21 |
| Forward P/E | 20.7× | 19.9× | 5th most expensive of 13 |
| Growth the price implies (Req g, 7 yrs) | 20.0% | 7.9% | 4th most demanding of 14 |
| Growth delivered (Del g) | +21.4% | +11.3% | 2nd highest of 14 |
| Hurdle (Req g minus delivered) | -1.4 pp | +6.5 pp | 7th least demanding of 14 |
| ROIC minus cost of capital | -2.8 pp | -1.3 pp | 9th lowest of 21 |
| EV / EBITDA | 13.5× | 14.3× | 5th cheapest of 9 |
| Net debt / EBITDA | 1.4× | 0.1× | 4th most indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Tinavi Medical Technologies 688277.SS | China | $872M | -36% | -2% | -59% | n/a | n/a | n/a |